Pencil Biosciences was founded in 2019 by Dr Rajik Ibrahim, Dr Timothy Schulz-Utermoehl and Dr Martin Quibell.
Now led by CEO Dr Amanda Smith, primary Founder and CTO Dr Rajik Ibrahim and Chair Dr Jon Moore, Pencil Biosciences will be deepening and widening the capabilities of its proprietary editing and modulation technology, which is modular in design, non-CRISPR in composition and significantly smaller than any Cas-based gene editing technologies.
Pencil’s technology will be utilised across a range of applications, providing new therapeutic options for patients with cancer, genetic and rare diseases. The technology also has potential for the treatment of infectious disease, novel diagnostics, and innovation in agriculture and cell line engineering.